Zhong, Wen-Zhao

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 959

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 440

Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer

Zhang, J.-T., Liu, S.-Y., Gao, W., Liu, S.-Y. M., Yan, H.-H., Ji, L., Chen, Y., Gong, Y., Lu, H.-L., Lin, J.-T., et al. (2022) · Cancer Discovery

Cancer Genomics and DiagnosticsLung Cancer Diagnosis and Treatment

Cited by 228

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer

Tu, H.-Y., Ke, E.-E., Yang, J.-J., Sun, Y.-L., Yan, H.-H., Zheng, M.-Y., Bai, X.-Y., Wang, Z., Su, J., Chen, Z.-H., et al. (2017) · Lung Cancer

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 182

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations

Yang, J. J., Zhou, Q., Yan, H. H., Zhang, X. C., Chen, H. J., Tu, H. Y., Wang, Z., Xu, C. R., Su, J., Wang, B. C., et al. (2017) · British Journal of Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 175

Toward an Expert Level of Lung Cancer Detection and Classification Using a Deep Convolutional Neural Network

Zhang, C., Sun, X., Dang, K., Li, K., Guo, X.-W., Chang, J., Yu, Z.-Q., Huang, F.-Y., Wu, Y.-S., Liang, Z., et al. (2019) · The Oncologist

AI in cancer detectionLung Cancer Diagnosis and Treatment

Cited by 168

EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas

Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., Yang, J.-J., Zhou, Q., Yan, H.-H., An, S.-J., et al. (2012) · The Oncologist

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 165

KRAS Mutation in Patients with Lung Cancer: A Predictor for Poor Prognosis but Not for EGFR-TKIs or Chemotherapy

Guan, J.-L., Zhong, W.-Z., An, S.-J., Yang, J.-J., Su, J., Chen, Z.-H., Yan, H.-H., Chen, Z.-Y., Huang, Z.-M., Zhang, X.-C., et al. (2013) · Annals of Surgical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 87

Clinical relevance of PD-L1 expression and CD8 T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer

Liu, S.-Y., Dong, Z.-Y., Wu, S.-P., Xie, Z., Yan, L.-X., Li, Y.-F., Yan, H.-H., Su, J., Yang, J.-J., Zhou, Q., et al. (2018) · Lung Cancer

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 85